作者
C Steven Ernest, Stephen D Hall, David R Jones
发表日期
2005/2/1
期刊
Journal of pharmacology and experimental therapeutics
卷号
312
期号
2
页码范围
583-591
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Human immunodeficiency virus (HIV) protease inhibitors (PIs) are inhibitors of CYP3A enzymes, but the mechanism is poorly defined. In this study, time- and concentration-dependent decreases in activity as defined by maximum rate of inactivation (kinact) and inhibitor concentration that gives 50% maximal inactivation (KI) of CYP3A by amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir were quantified using testosterone 6β-hydroxylation as a marker for CYP3A activity with recombinant CYP3A4(+b5), recombinant CYP3A5, and pooled human liver microsomes (HLMs). All the PIs, except indinavir, displayed inactivation with CYP3A4(+b5) and HLMs. Ritonavir was the most potent (KI = 0.10 and 0.17 μM) and demonstrated high kinact values (0.32 and 0.40 min-1) with both CYP3A4(+b5) and HLMs. Ritonavir was not significantly depleted by high-affinity binding with CYP3A4(+b5) and confirmed that …
引用总数
2005200620072008200920102011201220132014201520162017201820192020202120222023202441727312930221320131581099812874
学术搜索中的文章
CS Ernest, SD Hall, DR Jones - Journal of pharmacology and experimental …, 2005